Journal article
Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy
Asia-Pacific Journal of Clinical Oncology, Vol.17(6), pp.546-554
2021
PMID: 33460509
Abstract
Aim: To present findings from a longitudinal study on infection risk, mortality, and patient perspective of intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) treatment for patients with hypogammaglobulinemia secondary to hematological malignancy or its treatment (abbreviated as SID). Methods: Observational study period included final year of IVIg (13 patients) and of the first 3 years of SCIg (17 patients) with SID. Data were collected on clinical outcomes from medical records and patient perception via study specific questionnaire. Results: The median age was 63 years (53‐76 years), and for 82.4% of patients their hematological malignancy was in complete remission. The annual mean serum IgG trough levels remained stable over the 4 years and were 7.0 g/L (±2.77 g/L) with IVIg, and 8.0 g/L (±1.75 g/L), 8.7 g/L (±2.75 g/L), and 7.6 g/L (±2.89 g/L) (year 1, 2, and 3, respectively) with SCIg. While the annual infection rate was similar, the rate of hospitalization due to infection fluctuated, with 37%, 9%, 15%, and 32% in year 1, 2, 3, and 4 respectively. There were no systemic adverse events with IVIg or SCIg. Patients reported a strong preference for SCIg. One patient died due to progression of underlying disease and infection within the study period. Conclusion: SCIg was the preferred treatment mode over IVIg in our cohort, but both were well tolerated without any systemic adverse events in 4‐year follow up. The dosage and serum IgG levels were stable throughout. However, the number of infections requiring hospitalization fluctuated. It is anticipated that these findings encourage more hospitals to offer SCIg for SID patients.
Details
- Title
- Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy
- Authors
- Tanja M Windegger (Corresponding Author) - University of the Sunshine Coast, Queensland, School of Health and Sport Sciences - LegacyJanine English (Author) - Sunshine Coast University HospitalHelen Weston (Author) - Sunshine Coast Hospital and Health ServiceKaren Morwood (Author) - Sunshine Coast Hospital and Health ServiceMary Kynn (Author) - University of the Sunshine Coast, Queensland, School of Health and Sport Sciences - LegacyPaul Scuffham (Author) - Griffith UniversityYoke-Lin Fung (Author) - University of the Sunshine Coast, Queensland, School of Health and Sport Sciences - Legacy
- Publication details
- Asia-Pacific Journal of Clinical Oncology, Vol.17(6), pp.546-554
- Publisher
- Wiley-Blackwell Publishing Ltd.
- DOI
- 10.1111/ajco.13515
- ISSN
- 1743-7563
- PMID
- 33460509
- Organisation Unit
- School of Health and Sport Sciences - Legacy; University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy; School of Health - Biomedicine
- Language
- English
- Record Identifier
- 99506108702621
- Output Type
- Journal article
Metrics
20 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web Of Science research areas
- Oncology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites